LZTS2 Antibody
| Code | Size | Price |
|---|
| PSI-6635-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6635-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LZTS2 Antibody: LAPSER1, KIAA1813, LAPSER1, Leucine zipper putative tumor suppressor 2, Protein LAPSER1, hLZTS2
Application Note:
LZTS2 antibody can be used for detection of EPAC1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
LZTS2 Antibody: The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.
Background References:
- Thyssen G, Li TH, Lehmann L, et al. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol. Cell. Biol. 2006; 26:8857-67
- Sudo H and Maru Y. LAPSER1/LZTS2: a pluripotent tumor suppressor linked to the inhibition of katanin-mediated microtubule severing. Hum. Mol. Genet. 2008; 17:2524-40.
- Sudo H and Maru Y. LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 Katanin. FASEB J. 2007; 21:2086-100.
- Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, et al. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 2001; 20:6707-17.
Buffer:
LZTS2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (95%), Bovine: (95%)
Immunogen:
LZTS2 antibody was raised against a 19 amino acid synthetic peptide near the amino terminus of human LZTS2.
The immunogen is located within amino acids 80 - 130 of LZTS2.
The immunogen is located within amino acids 80 - 130 of LZTS2.
NCBI Gene ID #:
84445
NCBI Official Name:
leucine zipper, putative tumor suppressor 2
NCBI Official Symbol:
LZTS2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_115805
Protein GI Number:
45331215
Purification:
LZTS2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
LZTS2 antibody is predicted to not cross-react with other LZTS family members
Swissprot #:
Q9BRK4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LZTS2 Peptide | PSI-6635P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|